Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00434993 · ClinicalTrials.gov registry record · Phase 2
Drug Study of Albuterol to Treat Acute Lung Injury
A Phase 2 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 282
- Enrollment target
NCT00434993: Clinical Trial Phase 2 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00434993 is a Phase 2 study that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 282 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (112% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00434993, a Phase 2 study, was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 282 participants
- Enrollment target
Study Summary
Acute Respiratory Distress Syndrome (ARDS) and a lesser condition that occurs prior to ARDS, Acute Lung Injury (ALI), are medical conditions that occur when there is severe inflammation and increased fluids (edema) in both lungs, making it hard for the lungs to function properly. Patients with these conditions require treatment that includes the use of a breathing machine (ventilator). The purpose of this study is to find out whether giving albuterol (a drug commonly used in asthmatics) or not giving albuterol to patients with ALI or ARDS makes a difference in how long it takes for a patient to be able to breath without the ventilator.
Primary Outcome
Ventilator-free days (VFDs) is defined as the number of days from randomization to Day 28 after achieving unassisted breathing for patients who maintained unassisted breathing for at least two consecutive calendar days. If a patient achieved unassisted breathing, subsequently required additional assisted breathing, and once again achieved unassisted breathing, we counted only the VFDs after beginning the final period of unassisted breathing. Patients who died before Day 28 were assigned zero VFD
Interventions
- DRUG Placebo
- DRUG Albuterol Sulfate
- PROCEDURE Mini-Bronchoalveolar Lavage (BAL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Why NCT00434993 stopped before completion
NCT00434993 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (112% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00434993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00434993 about?
NCT00434993 is a clinical study titled "Drug Study of Albuterol to Treat Acute Lung Injury". Acute Respiratory Distress Syndrome (ARDS) and a lesser condition that occurs prior to ARDS, Acute Lung Injury (ALI), are medical conditions that occur when there is severe inflammation and increased fluids (edema) in both lungs, making it hard for the lungs to function properly. Patients with these...
What is the current status of trial NCT00434993?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2007-08. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00434993?
The interventions under investigation include: Placebo (DRUG), Albuterol Sulfate (DRUG), Mini-Bronchoalveolar Lavage (BAL) (PROCEDURE).
Who is sponsoring clinical trial NCT00434993?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00434993's enrollment target sits among peer trials
282 195th of 2000 higher than 1,805 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia